Preliminary efficacy of thalidomide in refractory Crohn's disease treatment
10.3760/cma.j.issn.0254-1432.2013.05.007
- VernacularTitle:沙利度胺治疗难治性克罗恩病的初步疗效观察
- Author:
Yinglian XIAO
;
Baili CHEN
;
Yao HE
;
Xiang GAO
;
Pinjin HU
;
Minhu CHEN
- Publication Type:Journal Article
- Keywords:
Crohn disease;
Thalidomide;
Treatment outcome;
Follow-up studies
- From:
Chinese Journal of Digestion
2013;(5):312-315
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the efficacy and safety of thalidomide in refractory Crohn's disease (CD).Methods A total of 21 moderate or severe active CD patients were enrolled,who had no response to glucocorticoid and azathioprine treatment or steroid-dependent.The patients were administrated with thalidomide 100 mg/d before sleep and followed up for one year.The clinical efficacy,endoscopic findings and safety were evaluated.Results Among 21 refractory CD patients,six patients stopped medication due to adverse effect and two because of ineffectiveness,three patients continued medication not completed one year follow-up,10 patients completed one year follow-up.The clinical remission,effective and ineffective rates were 23.8％(5/21),19.0％(4/21) and 57.1％(12/21) respectively.Under endoscope,the mucosal healing,improvement and no improvement rates were 9.5％(2/21),14.3％(3/21) and 76.2％ (16/21) respectively.The adverse effect rate was 71.4％ (15/21) including rash,conspitation,sommolence,numbness of hands and feet,leucopenia and muscular soreness.The mean time of the adverse effects onset was 3.4 weeks.Conclusions Thalidomide is effective in refractory CD treatment and could be used in patients unwilling to use biological medication or receive surgery.But the adverse effects should be noted.
